NO973659D0 - Anvendelse av LCK SH2-spesifikke forbindelser til behandling av autoimmune sykdommer og transplantatavvisning - Google Patents
Anvendelse av LCK SH2-spesifikke forbindelser til behandling av autoimmune sykdommer og transplantatavvisningInfo
- Publication number
- NO973659D0 NO973659D0 NO973659A NO973659A NO973659D0 NO 973659 D0 NO973659 D0 NO 973659D0 NO 973659 A NO973659 A NO 973659A NO 973659 A NO973659 A NO 973659A NO 973659 D0 NO973659 D0 NO 973659D0
- Authority
- NO
- Norway
- Prior art keywords
- lck
- treatment
- autoimmune diseases
- transplant rejection
- specific compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38638195A | 1995-02-10 | 1995-02-10 | |
| US40022095A | 1995-03-07 | 1995-03-07 | |
| US49735795A | 1995-06-30 | 1995-06-30 | |
| PCT/US1996/001964 WO1996024343A1 (en) | 1995-02-10 | 1996-02-09 | Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO973659D0 true NO973659D0 (no) | 1997-08-08 |
| NO973659L NO973659L (no) | 1997-10-08 |
Family
ID=27409758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO973659A NO973659L (no) | 1995-02-10 | 1997-08-08 | Anvendelse av LCK SH2-spesifikke forbindelser til behandling av autoimmune sykdommer og transplantatavvisning |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP0809490A4 (no) |
| JP (2) | JPH10513474A (no) |
| KR (1) | KR19980702115A (no) |
| AU (1) | AU4923796A (no) |
| BR (1) | BR9607614A (no) |
| CA (1) | CA2212645A1 (no) |
| FI (1) | FI973259A (no) |
| HU (1) | HUP9802078A3 (no) |
| NO (1) | NO973659L (no) |
| WO (1) | WO1996024343A1 (no) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922697A (en) * | 1996-10-02 | 1999-07-13 | Warner-Lambert Company | Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins |
| CN100469769C (zh) | 2003-03-24 | 2009-03-18 | 弗·哈夫曼-拉罗切有限公司 | 作为逆转录酶抑制剂的苄基-哒嗪酮 |
| CA2559552A1 (en) | 2004-03-23 | 2005-09-29 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994007913A1 (en) * | 1992-09-25 | 1994-04-14 | Warner-Lambert Company | Peptide antagonists of sh2 binding and therapeutic uses thereof |
| US5580979A (en) * | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
| US5710129A (en) * | 1995-02-23 | 1998-01-20 | Ariad Pharmaceuticals, Inc. | Inhibitors of SH2-mediated processes |
-
1996
- 1996-02-09 HU HU9802078A patent/HUP9802078A3/hu unknown
- 1996-02-09 WO PCT/US1996/001964 patent/WO1996024343A1/en not_active Application Discontinuation
- 1996-02-09 AU AU49237/96A patent/AU4923796A/en not_active Abandoned
- 1996-02-09 KR KR1019970705510A patent/KR19980702115A/ko not_active Application Discontinuation
- 1996-02-09 EP EP96905494A patent/EP0809490A4/en not_active Withdrawn
- 1996-02-09 JP JP8524486A patent/JPH10513474A/ja active Pending
- 1996-02-09 CA CA002212645A patent/CA2212645A1/en not_active Abandoned
- 1996-02-09 BR BR9607614A patent/BR9607614A/pt not_active Application Discontinuation
- 1996-02-12 JP JP8524493A patent/JPH10513564A/ja active Pending
- 1996-02-12 EP EP96906615A patent/EP0811159A1/en not_active Withdrawn
-
1997
- 1997-08-07 FI FI973259A patent/FI973259A/fi unknown
- 1997-08-08 NO NO973659A patent/NO973659L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI973259A (fi) | 1997-10-08 |
| HUP9802078A3 (en) | 1999-04-28 |
| KR19980702115A (ko) | 1998-07-15 |
| NO973659L (no) | 1997-10-08 |
| JPH10513564A (ja) | 1998-12-22 |
| WO1996024343A1 (en) | 1996-08-15 |
| BR9607614A (pt) | 1998-06-09 |
| FI973259A0 (fi) | 1997-08-07 |
| AU4923796A (en) | 1996-08-27 |
| HUP9802078A2 (hu) | 1998-12-28 |
| EP0809490A4 (en) | 1999-10-20 |
| CA2212645A1 (en) | 1996-08-15 |
| EP0811159A1 (en) | 1997-12-10 |
| JPH10513474A (ja) | 1998-12-22 |
| EP0809490A1 (en) | 1997-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO982172D0 (no) | Anvendelse av epinastin for behandling av smerter | |
| NO976063D0 (no) | Fremgangsmåte for behandling av diabetes | |
| NO962179D0 (no) | Fremgangsmåte for fremstilling av metallocen og anvendelse derav | |
| DK3695A (da) | Fremgangsmåde og anlæg til behandling af biologiske fluider | |
| DE69630479D1 (de) | Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten | |
| DE69412552T2 (de) | Medizinisches Instrument zur Behandlung von Sinusitis | |
| FI964874A (fi) | Vihannesten käsittely | |
| NO894296L (no) | Fremgangsmaate for behandling av leddgikt og betennelsessykdommer. | |
| DE69612465D1 (de) | Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen | |
| NO920780L (no) | Fremgangsmaate og anordning for behandling av epilepsi | |
| DE69426848D1 (de) | Gerät zur Behandlung von lichtempfindlichen Materialien | |
| DE69434492D1 (de) | Phosphodiesterase des menschlichen gehirns | |
| NO991459D0 (no) | Anvendelse av 1-hydroksy-2-pyridoner til behandling av hudinfeksjoner | |
| DE69807466T2 (de) | Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten | |
| EE9700235A (et) | Benseenamiidid neurodegeneratiivsete haiguste ravimiseks | |
| NO973659D0 (no) | Anvendelse av LCK SH2-spesifikke forbindelser til behandling av autoimmune sykdommer og transplantatavvisning | |
| NO910773D0 (no) | Koboltbasert knalegering og anvendelse av denne. | |
| NO973366D0 (no) | Fremgangsmåte for behandling av multippel sklerose | |
| NO982562D0 (no) | Sammensetning for behandling av smerte | |
| DE69412178D1 (de) | Apparat zur Behandlung von Lagen | |
| DK0670721T3 (da) | Lægemiddel til behandling og forebyggelse af knogle- og ledsygdomme | |
| NO307080B1 (no) | Fremgangsmåte for fremstilling av katalysatorer og anvendelse derav | |
| DE69737088D1 (de) | Therapeutisches agens zur behandlung von fiv infektionen | |
| NO931399D0 (no) | Anvendelse av naturstein | |
| NO951932L (no) | Behandling av infertilitet og forökning av fertiliseringskapasiteter |